SoftBank-backed Delhivery contests metrics in rival Ecom Express’ IPO filing

Date:

Share post:


Indian logistics firm Delhivery has publicly contested the accuracy of metrics presented by competitor Ecom Express in its draft initial public offering prospectus, a rare confrontation in the lead-up to the latter’s market debut. 

Delhivery, which is backed by SoftBank and already publicly listed, claims that Ecom Express has inaccurately represented Delhivery’s business metrics when drawing comparisons in its IPO filing. 

The 442-page draft prospectus (PDF) submitted by Ecom Express last month reported that the startup had shipped 514.41 million packages in the fiscal year ending March 2024, while Delhivery handled 740 million during the same period. 

Delhivery alleged in a filing to the stock exchanges Friday that this comparison is flawed, asserting that what it considers a single shipment is counted as two by its rivals, suggesting that Ecom Express’s volume figures are potentially inflated. (Delhivery says that its rivals count an order returned as two shipments.)

Delhivery further contests Ecom Express’s cost per shipment (CPS) calculations, citing disparities in accounting methods and alleging inflated shipment figures.

A slide from Delhivery’s filing Friday. (Image: Delhivery/BSE)

This public dispute comes less than a month after Ecom Express, which counts Warburg Pincus, Partners Group, and British International Investment among its backers, filed for an IPO aiming to raise $310 million. 

Delhivery has also questioned Ecom Express’s presentation of service EBITDA and corporate costs, citing a lack of consistent definitions for these metrics in the prospectus.

Ecom Express didn’t immediately respond to a request for comment.

This is a developing story. More to follow.



Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

OpenAI’s GPT-5 reportedly falling short of expectations

OpenAI’s efforts to develop its next major model, GPT-5, are running behind schedule, with results that don’t...

OpenAI announces new o3 model — but you can’t use it yet

Welcome back to Week in Review. This week, we’re looking at OpenAI’s last — and biggest —...

Google pushes back against DOJ’s ‘interventionist’ remedies in antitrust case

Google has offered up its own proposal in a recent antitrust case that saw the US Department...

If climate tech is dead, what comes next?

Humans have an innate desire to name things, but to be honest, we’re not always that good...

Hollywood angels: Here are the celebrities who are also star VCs

Becoming a venture capitalist has become the latest status symbol in Hollywood.  Everyone these days, from Olivia Wilde...

Meet Skyseed, a VC fund and incubator backing the Bluesky and AT Protocol ecosystem

On November 15, Peter Wang posted a message requesting ideas for a new incubator and fund to...

Sam Altman disputes Marc Andreessen’s description of AI meetings with Biden administration

Famed investor Marc Andreessen recently talked about meetings with Biden administration staff who gave him the impression...

EV startup Canoo places remaining employees on a ‘mandatory unpaid break’

Struggling electric van startup Canoo has placed its remaining employees on what it’s calling a “mandatory unpaid...